Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
MN Samtani, S Gopal, C Gassmann-Mayer, L Alphs… - CNS drugs, 2011 - Springer
Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic
recently approved by the US FDA and European Medicines Agency for use in patients with …
recently approved by the US FDA and European Medicines Agency for use in patients with …
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
MN Samtani, S Gopal, C Gassmann-Mayer, L Alphs… - CNS Drugs, 2011 - go.gale.com
Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic
recently approved by the US FDA and European Medicines Agency for use in patients with …
recently approved by the US FDA and European Medicines Agency for use in patients with …
Dosing and Switching Strategies for Paliperidone Palmitate
MN Samtani, S Gopal, C Gassmann-Mayer, L Alphs… - CNS Drugs, 2011 - infona.pl
Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic
recently approved by the US FDA and European Medicines Agency for use in patients with …
recently approved by the US FDA and European Medicines Agency for use in patients with …
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
MN Samtani, S Gopal, C Gassmann-Mayer, L Alphs… - CNS Drugs, 2011 - europepmc.org
Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic
recently approved by the US FDA and European Medicines Agency for use in patients with …
recently approved by the US FDA and European Medicines Agency for use in patients with …
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data
MN Samtani, S Gopal, C Gassmann-Mayer… - CNS …, 2011 - pubmed.ncbi.nlm.nih.gov
Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic
recently approved by the US FDA and European Medicines Agency for use in patients with …
recently approved by the US FDA and European Medicines Agency for use in patients with …
Dosing and Switching Strategies for Paliperidone Palmitate Based on Population Pharmacokinetic Modelling and Clinical Trial Data.
MN Samtani, S Gopal, C Gassmann-Mayer… - CNS …, 2011 - search.ebscohost.com
Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic
recently approved by the US FDA and European Medicines Agency for use in patients with …
recently approved by the US FDA and European Medicines Agency for use in patients with …
Dosing and Switching Strategies for Paliperidone Palmitate
MN Samtani, S Gopal, C Gassmann-Mayer… - CNS …, 2011 - search.proquest.com
Paliperidone palmitate is a second-generation, long-acting injectable (LAI) antipsychotic
recently approved by the US FDA and European Medicines Agency for use in patients with …
recently approved by the US FDA and European Medicines Agency for use in patients with …
[引用][C] Dosing and Switching Strategies for Paliperidone Palmitate: Based on Population Pharmacokinetic Modelling and Clinical Trial Data
MN SAMTANI, S GOPAL, C GASSMANN-MAYER… - CNS …, 2011 - pascal-francis.inist.fr
Dosing and Switching Strategies for Paliperidone Palmitate: Based on Population
Pharmacokinetic Modelling and Clinical Trial Data CNRS Inist Pascal-Francis CNRS Pascal …
Pharmacokinetic Modelling and Clinical Trial Data CNRS Inist Pascal-Francis CNRS Pascal …